AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20128041
Drug: Chemotherapy (vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vinorelbine plus cisplatin or gemcitabine plus cisplatin)
Trial: 16417182
Drug: Montelukast added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast added to previous medication for asthma treatment (4 weeks duration)
Trial: 16417182
Drug: Montelukast added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast added to previous medication for asthma treatment (8 weeks duration)
Trial: 7550184
Drug: Oral bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bromfenac
Trial: 1709239
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 0.1 nmol kg‐1 min‐1 (ADR‐L, n=8)
Trial: 1709239
Drug: Adrenaline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline infusion at 0.4 nmol kg‐1 min‐1 (ADR‐H, n=7)
Trial: 1709239
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (placebo, n=10)
Trial: 26343550
Drug: Glucagon 0.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon 0.11 to 0.44 mg and 0.33, 0.66 and 1 mg
Trial: 18606439
Drug: NAC (neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC (neoadjuvant chemotherapy) followed by surgery
Trial: 12114362
Drug: Inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin (TOBI), 300 mg, delivered by nebulizer, twice daily, in three 28-day on/28-day off treatment cycles
Trial: 7668873
Drug: Granisetron combined
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron combined with other antiemetic drugs
Trial: 2205418
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment with intravenous streptokinase
Trial: 2205418
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment with intravenous streptokinase within 3 hours of onset of symptoms
Trial: 27445266
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels <2.5 g/L
Trial: 22147444
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (maintenance or increase in immunosuppressive therapy)
Trial: 11318254
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied three times a week
Trial: 11318254
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied once daily
Trial: 11318254
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied twice daily
Trial: 11318254
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream applied three times a day
Trial: 11318254
Drug: Increased dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dosing frequency (from three times a week to three times a day)
Trial: 9137677
Drug: Cibenzoline (221
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (221 ± 60 mg daily)
Trial: 9137677
Drug: Flecainide (165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (165 ± 49 mg daily)
Trial: 7955972
Drug: Islet cell
RxNorm normalized name: Islet cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet cell antibodies (ICA) testing in previous GDM patients
Trial: 7955972
Drug: Islet cell
RxNorm normalized name: Islet cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet cell antibodies (ICA) positivity
Trial: 7955972
Drug: Insulin autoantibodies
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin autoantibodies (IAA) testing
Trial: 3555788
Drug: DAT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAT regimen (daunorubicin 70 mg/m2/day on Days 1‐3, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Trial: 3555788
Drug: TAD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAD regimen (daunorubicin 70 mg/m2/day on Days 5‐7, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Trial: 28425747
Drug: 10-session psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session psychiatric treatment augmented with the responsive intervention of the motive-oriented therapeutic relationship
Trial: 28425747
Drug: 10-session psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session psychiatric treatment
Trial: 23410714
Drug: Etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel implant (ENG-I)
Trial: 16648503
Drug: Irinotecan 65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 65 mg/m2 IV + cisplatin 30 mg/m2 IV on days 1 and 8 every 21 days
Trial: 16648503
Drug: Etoposide 120
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 120 mg/m2 IV on days 1 to 3 + cisplatin 60 mg/m2 IV on day 1 every 21 days
Trial: 8809212
Drug: Nitroglycerine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine administered sublingually
Trial: 1534248
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA)
Trial: 1534248
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with HD-MPA
Trial: 30823952
Drug: Inhaled glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoid combined with tiotropium bromide
Trial: 21631592
Drug: Implant-supported overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported overdentures (IOD)
Trial: 21631592
Drug: Implant-supported fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported fixed dental prostheses (IFDP)
Trial: 21631592
Drug: Implant-supported prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported prostheses (C/IOD and IFDP/IFDP)
Trial: 17659490
Drug: Interpersonal Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Psychotherapy (IPT) plus medication
Trial: 17659490
Drug: Medication plus
RxNorm normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication plus Clinical Management
Trial: 7682927
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 or 50 mg)
Trial: 3551051
Drug: Pankreon granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pankreon granules 20 g per day
Trial: 30174101
Drug: IANB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB with intraligamentary injection
Trial: 30174101
Drug: IANB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB with buccal injection
Trial: 23636182
Drug: Bone cement
RxNorm normalized name: bone cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone cement without antibiotic (control group)
Trial: 19289931
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or chemotherapy and radiotherapy combination
Trial: 15090880
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis within 3 hours
Trial: 15090880
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis beyond 3 hours with improved selection criteria
Trial: 11495257
Drug: Rifampicin in
RxNorm normalized name: Product containing rifampicin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin in fixed-dose combination (FDC) anti-tuberculosis formulations
Trial: 11495257
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion data
Trial: 9265935
Drug: Thiopental at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental at 10 micrograms/ml
Trial: 9265935
Drug: Thiopental at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental at 5 and 7.5 micrograms/ml
Trial: 8102107
Drug: HEEH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEEH and drugs
Trial: 8102107
Drug: Elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental diet (ED) therapy (more than 30 kcal/kg ideal body weight/day)
Trial: 3524428
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g every 8 h)
Trial: 3524428
Drug: Cefamandole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (2 g every 6 h)
Trial: 3524428
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g every 12 h)
Trial: 27657520
Drug: Albuterol MDPI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDPI 90 μg
Trial: 27523719
Drug: Albuterol MDPI
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol MDPI 180 μg
Trial: 27523719
Drug: Albuterol HFA
RxNorm normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol HFA 180 μg
Trial: 27657520
Drug: Albuterol HFA
RxNorm normalized name: Albuterol Sulfate 0.09 MG/1 ACTUATION Inhalation Aerosol Powder [ALBUTEROL HFA]
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol HFA 90 μg
Trial: 19260368
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and rectal non-steroidal pain-killers
Trial: 15915011
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 microg inhaled via HFA-134a inhaler (Modulite HFA)
Trial: 12891190
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy (administered immediately at local hospitals)
Trial: 10574676
Drug: Preresectional chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preresectional chemotherapy with mitomycin 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2, given intravenously on day 1 of each cycle at 3-week intervals followed by surgery.
Trial: 1761240
Drug: Gynatren (lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gynatren (lactobacillus vaccine)
Trial: 6282542
Drug: Disulfiram 250
RxNorm normalized name: disulfiram 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram 250 mg at bedtime
Trial: 24509938
Drug: Silicone gel
RxNorm normalized name: SILTREX Silicone Gel-Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone gel applied to the wound after stitch-out for 1 month
Trial: 17096458
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment assignment
Trial: 9659862
Drug: Guided self-change
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavior therapy)
Trial: 9659862
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (16 sessions of weekly cognitive behavior therapy)
Trial: 2540724
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lithium carbonate and imipramine hydrochloride
Trial: 19510
Drug: Butaclamol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butaclamol (up to 50 mg/day)
Trial: 19510
Drug: Butaclamol (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butaclamol (maintenance dose of 5 to 20 mg/day)
Trial: 25001274
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg and 80 mg
Trial: 16809729
Drug: Alfimeprase 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfimeprase 3.0 mg
Trial: 16809729
Drug: Alfimeprase 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfimeprase 1.0 mg
Trial: 16809729
Drug: Alfimeprase 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfimeprase 0.3 mg
Trial: 16809729
Drug: Alteplase 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 2.0 mg
Trial: 14663215
Drug: Hydrocortisone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (25 mg)
Trial: 10800630
Drug: Tetrazepam-ratiopharm film-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrazepam-ratiopharm film-coated tablets (test preparation)
Trial: 10800630
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of a reference preparation (reference preparation)
Trial: 8653995
Drug: Thioridazine 100
RxNorm normalized name: thioridazine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 100 mg for 14 days
Trial: 1458567
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) at 330 mg/m2 per week for colorectal cancer (167 mg/m2 daily for the first 3 months), Adriamycin (ADR) at 20 mg/m2 every 4 weeks, and mitomycin C (MMC) at 2.7 mg/m2 every 2 weeks for gastric cancer. 5-FU at 1,000 mg/m2 every week for 19 colorectal cancer patients.
Trial: 1458567
Drug: Implantable port
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable port system for repeated hepatic arterial infusion chemotherapy.
Trial: 17542340
Drug: C.E.R.A. (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. (all doses)
Trial: 14716711
Drug: Risperidone monotherapy
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone monotherapy (4.2 mg/day)
Trial: 11826488
Drug: Nitrullin in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrullin in combination with VPN
Trial: 9552059
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methotrexate with folinic acid rescue and continuing intrathecal methotrexate (HDMTX)
Trial: 9552059
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (ITMTX, HDMTX, CRTX)
Trial: 3048935
Drug: Ampicillin, 1
RxNorm normalized name: Ampicillin, 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 1 gm, four times daily, and metronidazole, 0.5 gm, three times daily, for 72 hours.
Trial: 23211454
Drug: Lavender and
RxNorm normalized name: PureLogic Hand Sanitizer French Lavender and Lemon Mint 6 Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender and Tea tree oils (group T) applied twice a day for 3 months
Trial: 23211454
Drug: Placebo (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (group P) applied twice a day for 3 months
Trial: 17301736
Drug: Amiodarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (400 mg/day for 3 days)
Trial: 15390234
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of ascorbate
Trial: 22076584
Drug: Nurse-prepared intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nurse-prepared intra-arterial flush solutions with longer hang times
Trial: 22076584
Drug: Nurse-prepared intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nurse-prepared intra-arterial flush solutions
Trial: 9499493
Drug: Intracoronary dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary dipyridamole (0.5 mg/kg body weight)
Trial: 9849048
Drug: Conventional pretreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pretreatment (heparin 15000 IE, aspirin 500 mg i.v.)
Trial: 2526009
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 400 mg teicoplanin 1, 3, 6 or 12 h prior to surgery
Trial: 1097143
Drug: Amiloride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (20 mg/day)
Trial: 1097143
Drug: Frusemide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (80 mg/day)
Trial: 1097143
Drug: Chlorothiazide (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (1000 mg/day)
Trial: 28407660
Drug: Calcium, 200
RxNorm normalized name: Fenoprofen Calcium, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium, 200 IU Vitamin D, and 90 µg Vitamin K supplementation
Trial: 8041983
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of lidocaine 2% (group B)
Trial: 2648150
Drug: Surfactant (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant (100 mg of phospholipid per kilogram of body weight [4 ml per kilogram])
Trial: 2648150
Drug: Air placebo
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air placebo (4 ml per kilogram)
Trial: 4825114
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin prophylaxis (5,000 IU mucous heparin sodium given two hours preoperatively and for five days post operatively)
Trial: 21803113
Drug: Rivastigmine 6
RxNorm normalized name: rivastigmine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 6 mg
Trial: 31430484
Drug: Cocaine administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine administration on day 10
Trial: 28410818
Drug: Protocol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol group received initial and additional doses of rocuronium (0.6 mg.kg−1 and 10 mg, respectively); blockade reversal with neostigmine (50 μg.kg−1); time ≥ 15 minutes between reversion and extubation.
Trial: 28410818
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received initial and additional doses of rocuronium, blockade reversal, neostigmine dose, and extubation time at the discretion of the anesthesiologist.
Trial: 24803523
Drug: Clinical dose
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical dose of esmolol
Trial: 24803523
Drug: Esmolol-treated groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol-treated groups (both clinical and subclinical doses)
Trial: 23474997
Drug: Taekwondo training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taekwondo training for 1 hour daily over three months
Trial: 16685298
Drug: Chlorhexidine rinse
RxNorm normalized name: chlorhexidine Mouthwash [Denti-Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week before and one week after surgery (group I)
Trial: 16685298
Drug: Chlorhexidine rinse
RxNorm normalized name: chlorhexidine Mouthwash [Denti-Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine rinse twice daily with 15 ml for 30 seconds for one week after surgery (group II)
Trial: 9431832
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone 1000 microg day-1 (F1000)
Trial: 9431832
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone 2000 microg day-1 (F2000)
Trial: 9431832
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 50 mg (PRED)
Trial: 9230722
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo (PL)
Trial: 8099863
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg isamoltane
Trial: 8099863
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg isamoltane
Trial: 3545744
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg Nisoldipine
Trial: 3545744
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Nisoldipine